Dublin, Sept. 16, 2024 (GLOBE NEWSWIRE) -- The "Saudi Arabia Pharmaceutical Market, By Region, Competition, Forecast & Opportunities, 2019-2029F" report has been added to ResearchAndMarkets.com's offering.
Saudi Arabia Pharmaceutical Market was valued at USD 9.01 Billion in 2023 and is expected to reach USD 13.99 Billion by 2029 with a CAGR of 7.57%
The Saudi Arabia pharmaceutical market is being driven by several key factors. Increasing healthcare expenditure, driven by Vision 2030's emphasis on enhancing healthcare infrastructure and services, is a major contributor. The rising prevalence of chronic diseases such as diabetes and cardiovascular conditions fuels demand for advanced pharmaceuticals.
The push for local pharmaceutical manufacturing and innovation, in alignment with the National Strategy for Industry, is fostering market growth. Investments in research and development, coupled with government initiatives to improve healthcare accessibility, further boost the market. The growth of medical tourism and the expansion of retail and online pharmaceutical channels also play significant roles in driving the sector's development. 
Key Market Trends
Advancements in medical research and development (R&D) are increasingly shaping the pharmaceutical market in Saudi Arabia. The country is making substantial investments in research facilities and forging strategic partnerships with global pharmaceutical companies to catalyze innovation and the development of novel drugs and therapies. This concerted focus on R&D is crucial for addressing the evolving healthcare needs of the population and enhancing treatment options available to patients.
Saudi Arabia's commitment to advancing medical R&D is reflected in the establishment and expansion of state-of-the-art research centers across the Kingdom. These facilities are equipped with cutting-edge technology and resources, enabling researchers to conduct high-quality studies and clinical trials. The growth of these centers not only boosts the capabilities for developing new medications but also attracts international researchers and pharmaceutical companies to collaborate on innovative projects. This influx of expertise and investment further accelerates the development of new therapies and drugs, contributing to the overall growth of the pharmaceutical market.
Collaborations with global pharmaceutical companies play a significant role in Saudi Arabia's R&D landscape. By partnering with established international firms, Saudi Arabia gains access to advanced technologies, knowledge, and best practices in drug development. These partnerships often involve joint research projects, technology transfers, and clinical trials conducted within the Kingdom. Such collaborations enhance the local pharmaceutical industry's ability to develop and commercialize new treatments and technologies, positioning Saudi Arabia as a key player in the global pharmaceutical market.
The focus on R&D also aligns with the Saudi Vision 2030, which emphasizes the diversification of the economy and the enhancement of the healthcare sector. As part of this vision, the government has been promoting initiatives that support innovation in medical research and development. This includes funding for research projects, support for startup biotech companies, and incentives for private sector investment in R&D activities. By aligning R&D efforts with national strategic goals, Saudi Arabia is not only addressing immediate healthcare needs but also ensuring long-term growth and sustainability in the pharmaceutical industry.
The growth of the pharmaceutical manufacturing sector in Saudi Arabia is a pivotal driver of the pharmaceutical market's expansion. The Kingdom's strategic focus on localizing pharmaceutical production is aimed at reducing its reliance on imported medications and achieving greater self-sufficiency. This initiative is part of a broader national strategy to enhance the resilience and sustainability of the healthcare system while fostering economic growth.
The Saudi government has introduced a range of measures to bolster domestic pharmaceutical manufacturing. These measures include financial incentives for local companies, regulatory support to streamline the approval process, and substantial investments in state-of-the-art manufacturing facilities. By creating a favorable environment for pharmaceutical manufacturers, the government is encouraging both local and international companies to establish or expand their production capabilities within the Kingdom.
One of the primary objectives of this localization effort is to reduce the dependency on imported drugs. Historically, Saudi Arabia has relied heavily on pharmaceutical imports to meet the needs of its population. By increasing local production, the Kingdom aims to mitigate supply chain vulnerabilities, enhance drug availability, and ensure a more stable and reliable supply of essential medications. This reduction in import dependence is particularly crucial in addressing the challenges posed by global supply chain disruptions and fluctuating international drug prices.
Supportive measures for domestic pharmaceutical manufacturing include a range of incentives such as tax breaks, subsidies, and funding for research and development. These incentives lower the barriers to entry for new companies and support the growth of existing ones. The government has established frameworks to facilitate the construction and operation of modern manufacturing facilities, ensuring that they meet international standards for quality and safety. This infrastructure development is critical for enhancing the capacity and capabilities of local pharmaceutical producers.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 80 |
| Forecast Period | 2023 - 2029 |
| Estimated Market Value (USD) in 2023 | $9.01 Billion |
| Forecasted Market Value (USD) by 2029 | $13.99 Billion |
| Compound Annual Growth Rate | 7.5% |
| Regions Covered | Saudi Arabia |
Report Scope:
Key Market Players
- Novartis Saudi Arabia
- Pfizer Saudi Limited Corporate
- Glenmark Saudi Arabia
- Tabuk Pharmaceuticals Manufacturing Co.
- Jamjoom Pharmaceuticals Co
- GSK Saudi Arabia
- AstraZeneca Saudi Arabia
- Sitco Pharma Co
- CAD Middle East Pharmaceutical Industries LLC
- Sudair Pharmaceutical Company
Saudi Arabia Pharmaceutical Market, By Drug Type:
- Generic Drugs
- Branded Drugs
Saudi Arabia Pharmaceutical Market, By Product Type:
- Prescription Drugs
- Over-The-Counter Drugs
Saudi Arabia Pharmaceutical Market, By Application:
- Cardiovascular
- Musculoskeletal
- Oncology
- Anti-infective
- Metabolic Disorder
- Others
Saudi Arabia Pharmaceutical Market, By Distribution Channel:
- Retail Pharmacy
- Hospital Pharmacy
- E-Pharmacy
Saudi Arabia Pharmaceutical Market, By Region:
- Western Region
- Central Region
- Southern Region
- Eastern Region
- Northern Region
For more information about this report visit https://www.researchandmarkets.com/r/ftbiow
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
